Aggressive protocol: 16-24 weeks for maximum results For significant aging or ambitious goals: Weeks 1-16: High-intensity phase Dose: 2-3mg per injection Frequency: 5-7x weekly (daily or near-daily) Total weekly: 10-21mg Topical: 2% serum twice daily (face/neck) Consider microneedling monthly Expected investment: 50mg vial lasts 2-5 weeks Need 3-8 vials for 16-week protocol Cost: $480-1,200 total More intensive but faster results Aggressive protocol timeline: Who should try aggressive: Age 50+ with significant aging Special events (wedding, reunion in 4-6 months) Have tried standard protocol with good results Want maximum possible improvement Can afford higher cost Who should avoid aggressive: First-time peptide users (start standard) Younger users (20s-30s, less to improve) Budget-conscious Impatient types (still takes 8+ weeks for visible results) Maintenance protocols after initial treatment Transitioning to maintenance: After achieving desired results (typically 12-24 weeks intensive) Goal shifts from improvement to preservation Reduce frequency and/or dose More sustainable long-term Maintenance dosing options: How long to maintain: Indefinite if want to keep results Stopping leads to gradual regression (see below) Most people choose lifelong maintenance Can cycle on/off but lose gains during off periods Periodic intensive bursts: Maintenance most of year Intensive protocol 8-12 weeks annually "Refresh" results Cost-effective long-term strategy See our peptide cycle planning guide and can you cycle different peptides
Although heavy chronic and recreational use of Nabiximols (Sativex ) can lead to addiction estimated at about 9% among all (recreational) Cannabis users (Panlilio et al., 2015), medical controlled applications indicate therapeutic potential and offer the potential for systematic analysis of cannabis use disorder
On the cell membrane, the cystine/glutamate antiporter SLC7A11/SLC3A2also known as system Xc transports extracellular cystine into the cell in a 1:1 exchange with intracellular glutamate release (101)
The FDAs Cardiovascular and Renal Drugs Advisory Committee voted 9-3 that patisirans benefits outweigh its risks in this indication, despite concerns expressed in FDA briefing documents prior to the adcomm meeting
Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients
NovoNordisk is currently in phase 3 trials to get oral semaglutide at a 50mg dosage approved for weight loss
